Sarepta CEO Vows To Get Exondys 51 Into EU Despite CHMP Negative Trend Vote
Executive Summary
CEO Doug Ingram aims to change EMA panel's view with a re-review, but concedes that EU arrival of the controversial DMD drug will now take longer than first thought.
You may also be interested in...
Deal Watch: Genentech Gets Down In The Dirt With Lodo Therapeutics
Genentech and Lodo will mine the soil microbiome to discover novel therapeutics. China’s Luye licenses commercial rights to AstraZeneca’s Seroquel franchise, while Sarepta picked up rights to gene therapy candidates from Myonexus, plus an option to acquire the company.
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
CDER Director Woodcock grants accelerated approval after FDA Commissioner Califf refuses to overturn her finding that the drug's effect on dystrophin is reasonably likely to predict clinical benefit in Duchenne muscular dystrophy.